JP Morgan Chase
UNCY icon

JP Morgan Chase’s Unicycive Therapeutics UNCY Stock Holding History

JP Morgan Chase’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78K Buy
+10,130
New +$74.7K ﹤0.01% 6223
2025
Q3 		– Sell
-21,709
Closed -$104K – 7737
2025
Q2 		$104K Buy
21,709
+21,691
+120,506% +$134K ﹤0.01% 5590
2025
Q1 		$106 Sell
18
-2
-10% -$12 ﹤0.01% 6867
2024
Q4 		$158 Sell
20
-1
-5% -$6 ﹤0.01% 6945
2024
Q3 		$84 Buy
21
+14
+200% +$56 ﹤0.01% 7028
2024
Q2 		$35 Buy
7
+2
+40% +$20 ﹤0.01% 7091
2024
Q1 		$65 Buy
+5
New +$61 ﹤0.01% 6981

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

JP Morgan Chase's UNCY Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 10,130 shares worth $78K. The stake represents ﹤0.01% of the portfolio and ranks #6223 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in UNCY as recently as Q2 2025.

JP Morgan Chase first reported a position in UNCY in Q1 2024 and has held it in 7 quarters since. The position peaked at $104K in Q2 2025. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • JP Morgan Chase held 10,130 shares of Unicycive Therapeutics worth $78K as of Q2 2026.
  • Unicycive Therapeutics was a new JP Morgan Chase position in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6223 holding.
  • JP Morgan Chase first reported a position in Unicycive Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's Unicycive Therapeutics position peaked at $104K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.